Page last updated: 2024-11-04

beta-glycerophosphoric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-glycerophosphoric acid: plays role in mineralization of bone in vitro [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycerol 2-phosphate : A glycerol monophosphate having the phosphate group at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2526
CHEMBL ID1232903
CHEBI ID17270
SCHEMBL ID59773
MeSH IDM0098836

Synonyms (41)

Synonym
CHEMBL1232903
beta-glycerophosphate ,
CHEBI:17270 ,
1,2,3-propanetriol, 2-(dihydrogen phosphate)
2-glycerophosphate
glycerol 2-(dihydrogen phosphate)
1,3-hydroxy-2-propyl dihydrogen phosphate
glycerophosphoric acid ii
2-hydroxy-1-(hydroxymethyl)ethyl dihydrogen phosphate
17181-54-3
C02979
glycerol 2-phosphate
beta-glycerophosphoric acid
glycerol-2-phosphate
DB01779
einecs 241-228-2
beta-gp
2-glycerophosphoric acid
B9985BAA-A85D-444F-B350-1ADB9CB72031
1,3-dihydroxypropan-2-yl dihydrogen phosphate
wwh06g87w6 ,
unii-wwh06g87w6
SCHEMBL59773
glycerol, 2-(dihydrogen phosphate)
.beta.-glycerophosphate
glyceryl 2-phosphate
glycerophosphoric acid .beta.-form
.beta.-glycerophosphoric acid
.beta.-glyceryl phosphate
dihydrogen .beta.-glycerophosphate
glycerophosphoric acid .beta.-form [mi]
DHCLVCXQIBBOPH-UHFFFAOYSA-N
HMS3604K07
DTXSID1023106
[(1,3-dihydroxypropan-2-yl)oxy]phosphonic acid
beta-glycerophosphorate
glycerinphosphorsaure
glycerol-beta-phosphate
Q21099098
beta-glycerophosphoric-acid
EN300-7329809

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Further, the in vivo pharmacokinetic characteristics of DTX-C/GP correlated well with the in vitro release."( Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel.
Chen, X; Dai, Y; Deng, S; Li, C; Liu, Q; Ren, S; Tian, F; Wang, X; Zhao, J; Zhou, S, 2014
)
0.4
" The results suggested that subcutaneous injection of thermosensitive in situ hydrogels may be used to achieve sustained exposure of protein therapeutics which have a very short half-life and thus require frequent administration."( Pharmacokinetic Evaluation of Thermosensitive Sustained Release Formulations Developed for Subcutaneous Delivery of Protein Therapeutics.
Rajadhyaksha, PM; Shah, DK; Shastri, DH, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"To study the feasibility of human adipose-derived stem cells (hADSCs) combined with small intestinal submucosa powder (SISP)/chitosan chloride (CSCl)-β-glycerol phosphate disodium (GP)-hydroxyethyl cellulose (HEC) for adipose tissue engineering."( [HUMAN ADIPOSE-DERIVED STEM CELLS COMBINED WITH SMALL INTESNITAL SUBMUCOSA POWDER/CHITOSAN CHLORIDE-β-GLYCEROL PHOSPHATE DISODIUM-HYDROXYETHYL CELLULOSE HYBRID FOR ADIPOSE TISSUE ENGINEERING].
Deng, X; Lü, Q; Luo, J; Xiong, B; Zhang, S, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
"85%, indicating that the bioavailability of insulin was significantly enhanced by NP-CS/GP gels."( Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin.
Gong, T; Peng, Q; Sun, X; Tan, J; Wu, CY; Zhang, T; Zhang, ZR, 2013
)
0.39
" Moreover, the nanogel/gel exhibited no cytotoxicity by MTT assay, and the oral bioavailability of Myr in rats was improved with an accelerated absorption rate after Myr was loaded into CS/β-GP nanogel/gel."( Preparation and evaluation of chitosan-based nanogels/gels for oral delivery of myricetin.
Ji, G; Li, G; Meng, Q; Shen, H; Wang, H; Xia, M; Xie, Y; Yao, Y, 2016
)
0.43
" Although eye drops, a non-invasive topical treatment, could be a potential strategy to reduce side effects, it remains challenging to apply due to limited bioavailability mainly linked to poor retention time and permeation capacity for eye biological barriers."( Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment.
Bai, J; Chen, Z; Deng, J; Feng, Y; He, H; Huang, J; Jiang, Z; McAlinden, C; Mei, C; Pan, L; Skiadaresi, E; Wang, Q; Xu, H; Xu, W; Yang, M; Ye, X; Yu, J; Zeng, Z; Zhang, J, 2021
)
0.62
"25%β-CaGPn into 1100F formulation increased the bioavailability of calcium and phosphate, promoting a higher remineralizing effect."( Effect of the association of microparticles and nano-sized β-calcium glycerophosphate in conventional toothpaste on enamel remineralization: In situ study.
Danelon, M; de Camargo, ER; Delbem, ACB; Emerenciano, NG; Gonçalves, FMC; Quinteiro, JP; Silva-Sousa, YTC, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
"Sustained release thermosensitive solution containing cytarabine-loaded liposome delivery system offers the possibility of reduced dosing frequency and sustained drug action."( Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine.
Kulkarni, V; Mulik, R; Murthy, RS, 2009
)
0.35
" In addition, it was possible to modify the drug dosage within Lipogel by varying the duration of hyperthermia."( A stimuli responsive liposome loaded hydrogel provides flexible on-demand release of therapeutic agents.
Deckers, R; Duffy, GP; Hastings, CL; Hennink, WE; Herron, CC; Kelly, HM; Lopez Noriega, A; McDonnell, CO; O'Brien, FJ; O'Neill, HS; Ruiz-Hernández, E, 2017
)
0.46
" This hydrogel platform demonstrates remarkable flexibility in terms of drug scheduling and sequencing, enabling the release of multiple agents and the ability to control drug dosing in a minimally invasive fashion."( A stimuli responsive liposome loaded hydrogel provides flexible on-demand release of therapeutic agents.
Deckers, R; Duffy, GP; Hastings, CL; Hennink, WE; Herron, CC; Kelly, HM; Lopez Noriega, A; McDonnell, CO; O'Brien, FJ; O'Neill, HS; Ruiz-Hernández, E, 2017
)
0.46
" The developed sustained release in situ gel formulations could enhance patient's compliance by reducing the dosing frequency and also act as an alternative treatment to curb periodontitis."( Investigation on solution-to-gel characteristic of thermosensitive and mucoadhesive biopolymers for the development of moxifloxacin-loaded sustained release periodontal in situ gels.
Jnanendrappa, N; Meka, VS; Quah, SY; Sahu, PS; Sheshala, R; Tan, GC, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
glycerol monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
AtMetExpress overview0109
Differentiation pathway012
Pluripotent stem cell differentiation pathway011

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
DNA repairEyes absent homolog 2Homo sapiens (human)
chromatin remodelingEyes absent homolog 2Homo sapiens (human)
mesodermal cell fate specificationEyes absent homolog 2Homo sapiens (human)
striated muscle tissue developmentEyes absent homolog 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
mitochondrial outer membrane permeabilizationEyes absent homolog 2Homo sapiens (human)
anatomical structure developmentEyes absent homolog 2Homo sapiens (human)
positive regulation of DNA repairEyes absent homolog 2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandEyes absent homolog 2Homo sapiens (human)
cell differentiationEyes absent homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
magnesium ion bindingEyes absent homolog 2Homo sapiens (human)
protein bindingEyes absent homolog 2Homo sapiens (human)
histone H2AXY142 phosphatase activityEyes absent homolog 2Homo sapiens (human)
protein tyrosine phosphatase activityEyes absent homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmEyes absent homolog 2Homo sapiens (human)
mitochondrionEyes absent homolog 2Homo sapiens (human)
cytosolEyes absent homolog 2Homo sapiens (human)
nucleusEyes absent homolog 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (486)

TimeframeStudies, This Drug (%)All Drugs %
pre-199047 (9.67)18.7374
1990's102 (20.99)18.2507
2000's111 (22.84)29.6817
2010's189 (38.89)24.3611
2020's37 (7.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.65 (24.57)
Research Supply Index6.22 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.40%)5.53%
Reviews3 (0.60%)6.00%
Case Studies1 (0.20%)4.05%
Observational0 (0.00%)0.25%
Other493 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]